TXT-0300

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTXT-0300
Drug Alias NameNMDA NR2B antagonist (Traxion)NMDA receptor epsilon 2 subunit inhibitor (Traxion)TXT-0300
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor subunit epsilon 2 antagonists
TargetsGlutamate [NMDA] receptor subunit epsilon 2
Therapy Area/IndicationsNeuralgia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTraxion Therapeutics IncJohns Hopkins University
Active IndicationsN/A
Inactive IndicationsNeuralgia

Other Information

ATC CodeN/A
Related LinksN/A